• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Genomic medicine for heart failure prediction in patients with atrial fibrillation.

作者信息

Wijdeveld Leonoor F J M, Jurgens Sean J

机构信息

Department of Physiology, Amsterdam Cardiovascular Sciences, Heart Failure & Arrhythmias, Amsterdam UMC Location Vrije Universiteit, Amsterdam, De Boelelaan 1117, 1081 HV, the Netherlands.

Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, 415 Main Street Cambridge, MA 02142, USA.

出版信息

Europace. 2025 Jul 1;27(7). doi: 10.1093/europace/euaf113.

DOI:10.1093/europace/euaf113
PMID:40474646
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12212050/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2048/12212050/a584eefd7464/euaf113_ga.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2048/12212050/a584eefd7464/euaf113_ga.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2048/12212050/a584eefd7464/euaf113_ga.jpg

相似文献

1
Genomic medicine for heart failure prediction in patients with atrial fibrillation.用于预测心房颤动患者心力衰竭的基因组医学。
Europace. 2025 Jul 1;27(7). doi: 10.1093/europace/euaf113.
2
Polygenic risk-based prediction of heart failure in young patients with atrial fibrillation: an analysis from UK Biobank.基于多基因风险的年轻房颤患者心力衰竭预测：来自英国生物银行的分析。
Europace. 2025 Jul 1;27(7). doi: 10.1093/europace/euaf104.
3
Effects of Atrial Fibrillation Ablation for Heart Failure With Preserved Ejection Fraction: Insights From CABANA.射血分数保留的心力衰竭患者行房颤消融术的效果：来自CABANA研究的见解
JACC Heart Fail. 2025 May;13(5):785-794. doi: 10.1016/j.jchf.2025.01.029. Epub 2025 Apr 16.
4
Management of atrial flutter and atrial fibrillation with rapid ventricular response in patients with acute decompensated heart failure: A systematic review.急性失代偿性心力衰竭患者伴有快速心室反应的心房扑动和心房颤动的治疗：系统评价。
Acad Emerg Med. 2023 Feb;30(2):124-132. doi: 10.1111/acem.14618. Epub 2022 Dec 5.
5
Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.地高辛治疗心房颤动和心房扑动：随机临床试验的系统评价与荟萃分析和试验序贯分析。
PLoS One. 2018 Mar 8;13(3):e0193924. doi: 10.1371/journal.pone.0193924. eCollection 2018.
6
Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: A systematic review and meta-analysis.心房颤动与心肌梗死、全因死亡率和心力衰竭风险：系统评价和荟萃分析。
Eur J Prev Cardiol. 2017 Sep;24(14):1555-1566. doi: 10.1177/2047487317715769. Epub 2017 Jun 15.
7
Cryoballoon ablation for atrial fibrillation in patients with heart failure and reduced left ventricular ejection fraction: A systematic review and meta-analysis.冷冻球囊消融治疗心力衰竭伴左心室射血分数降低的心房颤动：系统评价和荟萃分析。
Clin Cardiol. 2024 Jan;47(1):e24177. doi: 10.1002/clc.24177. Epub 2023 Oct 25.
8
Colchicine for cardiovascular medicine: a systematic review and meta-analysis.秋水仙碱在心血管医学中的应用：系统评价和荟萃分析。
Future Cardiol. 2022 Aug;18(8):647-659. doi: 10.2217/fca-2020-0206. Epub 2022 Jul 5.
9
Underuse of oral anticoagulants in atrial fibrillation: a systematic review.房颤患者中口服抗凝剂的使用率较低：一项系统评价。
Am J Med. 2010 Jul;123(7):638-645.e4. doi: 10.1016/j.amjmed.2009.11.025.
10
Effect of RAAS blockers on adverse clinical outcomes in high CVD risk subjects with atrial fibrillation: A meta-analysis and systematic review of randomized controlled trials.肾素-血管紧张素-醛固酮系统阻滞剂对高心血管疾病风险的房颤患者不良临床结局的影响：一项随机对照试验的荟萃分析和系统评价
Medicine (Baltimore). 2016 Jun;95(26):e4059. doi: 10.1097/MD.0000000000004059.

本文引用的文献

1
Polygenic risk-based prediction of heart failure in young patients with atrial fibrillation: an analysis from UK Biobank.基于多基因风险的年轻房颤患者心力衰竭预测：来自英国生物银行的分析。
Europace. 2025 Jul 1;27(7). doi: 10.1093/europace/euaf104.
2
Cardiomyopathy-Associated Gene Variants in Atrial Fibrillation.心房颤动中与心肌病相关的基因变异
JAMA Cardiol. 2025 Apr 30. doi: 10.1001/jamacardio.2025.0460.
3
Sequencing in over 50,000 cases identifies coding and structural variation underlying atrial fibrillation risk.对超过50000例病例进行测序，确定了房颤风险背后的编码和结构变异。
Nat Genet. 2025 Mar;57(3):548-562. doi: 10.1038/s41588-025-02074-9. Epub 2025 Mar 6.
4
Meta-analysis of genome-wide associations and polygenic risk prediction for atrial fibrillation in more than 180,000 cases.超过180,000例心房颤动病例的全基因组关联荟萃分析及多基因风险预测
Nat Genet. 2025 Mar;57(3):539-547. doi: 10.1038/s41588-024-02072-3. Epub 2025 Mar 6.
5
Spotlight on the 2024 ESC/EACTS management of atrial fibrillation guidelines: 10 novel key aspects.聚焦2024年欧洲心脏病学会/欧洲心胸外科学会心房颤动管理指南：10个新的关键方面。
Europace. 2024 Dec 3;26(12). doi: 10.1093/europace/euae298.
6
Integrative proteomic analyses across common cardiac diseases yield mechanistic insights and enhanced prediction.对常见心脏病进行的综合蛋白质组学分析揭示了其机制并提高了预测能力。
Nat Cardiovasc Res. 2024 Dec;3(12):1516-1530. doi: 10.1038/s44161-024-00567-0. Epub 2024 Nov 21.
7
Integrating metabolomics and proteomics to identify novel drug targets for heart failure and atrial fibrillation.整合代谢组学和蛋白质组学，以鉴定心力衰竭和心房颤动的新型药物靶点。
Genome Med. 2024 Oct 21;16(1):120. doi: 10.1186/s13073-024-01395-4.
8
2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).2024年欧洲心脏病学会（ESC）心房颤动管理指南，与欧洲心胸外科学会（EACTS）联合制定。
Eur Heart J. 2024 Sep 29;45(36):3314-3414. doi: 10.1093/eurheartj/ehae176.
9
Genetic testing in early-onset atrial fibrillation.早发性心房颤动的基因检测。
Eur Heart J. 2024 Sep 7;45(34):3111-3123. doi: 10.1093/eurheartj/ehae298.
10
Heart Failure-Related Death in Subjects With Atrial Fibrillation in the United States, 1999 to 2020.美国 1999 年至 2020 年房颤患者的心力衰竭相关性死亡。
J Am Heart Assoc. 2024 May 7;13(9):e033897. doi: 10.1161/JAHA.123.033897. Epub 2024 Apr 30.